HIV patients pause meds in closely watched study

NCT ID NCT04359186

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study pauses HIV medication in 40 volunteers to closely monitor how the virus and body interact during the earliest stages of rebound. Participants stop their antiretroviral therapy and undergo frequent testing, resuming treatment within three weeks. The goal is to learn more about HIV persistence, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could reveal how HIV rebounds after stopping medication, guiding future strategies for long-term remission.

What could go wrong

This is a small, early-stage observational study with no direct treatment benefit. Participants may experience virus rebound or side effects from stopping therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV/AIDS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94110, United States

    Contact Email: •••••@•••••